You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Investigational Drug Information for rimiducid


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug rimiducid?

rimiducid is an investigational drug.

There have been 22 clinical trials for rimiducid. The most recent clinical trial was a Phase 1 trial, which was initiated on December 27th 2018.

The most common disease conditions in clinical trials are Myelodysplastic Syndromes, Preleukemia, and Leukemia, Myeloid, Acute. The leading clinical trial sponsors are Bellicum Pharmaceuticals, Poseida Therapeutics, Inc., and National Cancer Institute (NCI).

There are eight US patents protecting this investigational drug and eighty-seven international patents.

Recent Clinical Trials for rimiducid
TitleSponsorPhase
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)Bellicum PharmaceuticalsPhase 1
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)M.D. Anderson Cancer CenterPhase 1
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid TumorsPoseida Therapeutics, Inc.Phase 1

See all rimiducid clinical trials

Clinical Trial Summary for rimiducid

Top disease conditions for rimiducid
trials0123456789Myelodysplastic SyndromesPreleukemiaLeukemia, Myeloid, AcuteNeoplasms[disabled in preview]
Top clinical trial sponsors for rimiducid
trials0246810121416Bellicum PharmaceuticalsPoseida Therapeutics, Inc.National Cancer Institute (NCI)[disabled in preview]

See all rimiducid clinical trials

US Patents for rimiducid

DrugnamePatent NumberPatent TitlePatent AssigneeEstimated Expiration
rimiducid ⤷  Subscribe Compositions and methods for treatment of cancer Aleta Biotherapeutics Inc. (Natick, MA) ⤷  Subscribe
rimiducid ⤷  Subscribe Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) ⤷  Subscribe
rimiducid ⤷  Subscribe Treatment of cancer using GFR .alpha.-4 chimeric antigen receptor THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (Philadelphia, PA) NOVARTIS AG (Basel, CH) THE SCRIPPS RESEARCH INSTITUTE (La Jolla, CA) ⤷  Subscribe
rimiducid ⤷  Subscribe Treatment of cancer using a CD33 chimeric antigen receptor Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) ⤷  Subscribe
>Drugname>Patent Number>Patent Title>Patent Assignee>Estimated Expiration
Showing 1 to 4 of 4 entries

International Patents for rimiducid

DrugnameCountryDocument NumberEstimated ExpirationRelated US Patent
rimiducid Australia AU2016343809 2035-10-30 ⤷  Subscribe
rimiducid Brazil BR112018008326 2035-10-30 ⤷  Subscribe
rimiducid Canada CA3002674 2035-10-30 ⤷  Subscribe
rimiducid Chile CL2018001152 2035-10-30 ⤷  Subscribe
>Drugname>Country>Document Number>Estimated Expiration>Related US Patent
Showing 1 to 4 of 4 entries

Rimiducid: A Promising Drug Candidate in Cellular Immunotherapy

Introduction

Rimiducid, a homodimerizing agent, is a pivotal drug candidate in the realm of cellular immunotherapies, particularly for the treatment of cancers and blood disorders. Developed by Bellicum Pharmaceuticals, rimiducid is designed to enhance the therapeutic effectiveness of immunotherapies by controlling and amplifying immune cell activity.

Mechanism of Action

Rimiducid is a lipid-permeable tacrolimus analogue and a protein dimerizer. It works through chemically-inducible dimerization (CID) technologies, binding to switch proteins and dimerizing them, which triggers a downstream signaling cascade. This mechanism allows for the precise control and enhancement of immune cell function, making it a valuable component in combination therapies[3].

Clinical Trial Updates

BPX-601 GoCAR-T in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Rimiducid is being used in conjunction with BPX-601, a GoCAR-T product candidate, in clinical trials for mCRPC. The Phase 1/2 trials have shown positive interim data, with no dose-limiting toxicities observed. The adverse events were comparable to those seen with previous treatments, and there was notable anti-tumor activity in a heavily pre-treated patient population. Enrollment is ongoing, with results expected to be presented at a medical meeting in the near future[1].

BPX-603 Dual-Switch GoCAR-T in HER2+ Solid Tumors

In another significant development, rimiducid is part of the BPX-603 dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for patients with HER2+ solid tumors, including breast, endometrial, ovarian, gastric, and colorectal cancers. This product incorporates Bellicum’s iMC activation and CaspaCIDe safety switch technologies, aimed at enhancing cell proliferation, persistence, and anti-tumor effect while managing adverse events. Enrollment is ongoing at dose level 2, with results anticipated for presentation in 2022[1].

Safety and Efficacy

The early clinical data from both BPX-601 and BPX-603 trials indicate manageable safety profiles. Charity Scripture, PharmD, Chief Development Officer of Bellicum, highlighted the encouraging early clinical activity and the lack of clinical efficacy at the initial low dose in the BPX-603 trial as being in line with expectations. This suggests that rimiducid, when used in combination with these GoCAR-T products, can be safely administered and potentially offer significant therapeutic benefits[1].

Market Projection

Growing Demand for Targeted Therapies

The market for targeted cancer therapies, including those involving homodimerizing agents like rimiducid, is expected to grow significantly. The radionuclide drug conjugates (RDC) market, which also involves targeted therapies, is predicted to witness a 13.9% CAGR from 2024 to 2031. This growth is driven by technological advancements, regulatory approvals, and the increasing adoption of innovative cancer treatments[5].

Regional Dominance

North America is expected to lead the market for targeted cancer therapies, including those involving rimiducid, due to a robust product pipeline, increased regulatory approvals, and a favorable environment for research and development. The presence of major pharmaceutical companies and a well-developed healthcare infrastructure further supports this dominance[5].

Competitive Landscape

Rimiducid is part of a broader landscape of immunotherapies and targeted cancer treatments. Companies like Bellicum Pharmaceuticals, Poseida Therapeutics, and others are actively developing and testing various product candidates to address unmet medical needs in cancer treatment. The competitive edge of rimiducid lies in its ability to enhance and control immune cell activity, making it a valuable asset in combination therapies[1][2].

Future Outlook

As clinical trials progress and more data becomes available, the potential of rimiducid to become a key component in cancer treatment regimens is likely to increase. The ongoing enrollment and future presentations of clinical trial results will be crucial in determining the full efficacy and safety profile of rimiducid in combination with GoCAR-T products.

Key Takeaways

  • Mechanism of Action: Rimiducid works through chemically-inducible dimerization, enhancing immune cell activity.
  • Clinical Trials: Positive interim data from Phase 1/2 trials for BPX-601 and BPX-603, with manageable safety profiles.
  • Market Growth: Expected growth in the targeted cancer therapies market, driven by technological advancements and regulatory approvals.
  • Regional Dominance: North America is anticipated to lead the market due to its robust product pipeline and favorable research environment.
  • Competitive Landscape: Rimiducid is part of a competitive landscape of immunotherapies, offering unique benefits in combination therapies.

FAQs

What is rimiducid and how does it work?

Rimiducid is a homodimerizing agent used in combination with cellular immunotherapies to enhance therapeutic effectiveness. It works by binding to switch proteins and triggering a downstream signaling cascade through chemically-inducible dimerization.

Which clinical trials is rimiducid currently involved in?

Rimiducid is currently involved in Phase 1/2 clinical trials for BPX-601 in metastatic castration-resistant prostate cancer (mCRPC) and for BPX-603 in HER2+ solid tumors.

What are the safety profiles observed in the clinical trials?

The clinical trials have shown manageable safety profiles, with no dose-limiting toxicities observed and adverse events comparable to previous treatments.

How does rimiducid fit into the broader market of targeted cancer therapies?

Rimiducid is part of a growing market for targeted cancer therapies, expected to see significant growth driven by technological advancements and regulatory approvals.

What is the regional outlook for the market involving rimiducid?

North America is expected to lead the market for targeted cancer therapies, including those involving rimiducid, due to its robust product pipeline and favorable research environment.

Sources

  1. Bellicum Announces Positive Interim Data from Phase 1/2 GoCAR-T Studies, Secures $35 Million Private Placement Equity Financing Priced at Market. Biospace.
  2. SEC Filing | Poseida Therapeutics, Inc.. Investors Poseida.
  3. Rimiducid: Uses, Interactions, Mechanism of Action | DrugBank Online. DrugBank.
  4. ARIAD Pharmaceuticals - Wikipedia. Wikipedia.
  5. Radionuclide Drug Conjugates (RDC) Market Size, Share & Trends. InsightAce Analytic.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.